MHRAsafety guidance83% confidence
Guidance: AI Airlock Sandbox Phase 2 Programme Report
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to COVAC-2.
Regulatory Analysis
The MHRA’s AI Airlock second phase ran between April 2025 and May 2026. This report does not constitute formal MHRA guidance.
Supporting Context
- Therapeutic area
- Infectious Disease · COVID-19
- Sub-indication
- General
Related signal: COVAC-2 Vaccine Shows Safety and Immunogenicity as COVID-19 Booster in Phase 1 Trial
Source
FDA document
View source